Albion Financial Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Albion Financial Group’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	687
2021 Q4	$0	Buy	+1	New	+$6	﹤0.01%	713

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Albion Financial Group's SRNE Position: Q1 2022 in Review

Albion Financial Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 1 share.

Albion Financial Group first reported a position in SRNE in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Albion Financial Group reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Albion Financial Group sold 1 Sorrento Therapeutics, Inc. share in Q1 2022.
Albion Financial Group first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 1 quarter.
Albion Financial Group's Sorrento Therapeutics, Inc. position peaked at $0 in Q4 2021.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Albion Financial Group's 13F filing for Q1 2022, filed 9 May 2022.